Compare · BSX vs OFIX
BSX vs OFIX
Side-by-side comparison of Boston Scientific Corporation (BSX) and Orthofix Medical Inc. (OFIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and OFIX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $71.46B, about 170.7x OFIX ($418.7M).
- Over the past year, BSX is down 52.0% and OFIX is down 20.7% - OFIX leads by 31.3 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 6 for OFIX).
- BSX has more recent analyst coverage (25 ratings vs 10 for OFIX).
- Company
- Boston Scientific Corporation
- Orthofix Medical Inc.
- Price
- $49.32+0.09%
- $10.27-3.20%
- Market cap
- $71.46B
- $418.7M
- 1M return
- +9.65%
- -10.46%
- 1Y return
- -52.00%
- -20.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 12
- 6
- Recent ratings
- 25
- 10
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
Latest BSX
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
- Boston Scientific downgraded by Argus
- Penumbra, Inc. Reports Second Quarter 2026 Financial Results
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest OFIX
- SEC Form S-8 filed by Orthofix Medical Inc.
- SEC Form 10-Q filed by Orthofix Medical Inc.
- Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
- MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
- Orthofix to Participate in Upcoming Investor Conferences
- Orthofix to Report Second Quarter 2026 Financial Results
- Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Pres, Global Ops & Qual Mcpherron Aviva sold $34,425 worth of shares (3,670 units at $9.38), decreasing direct ownership by 5% to 66,330 units (SEC Form 4) to cover withholding tax
- Director Bazaar Alan Lee was granted 14,965 shares, increasing direct ownership by 30% to 65,489 units (SEC Form 4)